Share
Film Screening The Cholesterol Code Screening
Virtual Event Cinema℠ Sat, Apr 18, 2026 at 9:30 AM CDT 2 hrs
Hosted by Ravi Kamepalli
Watch Trailer
× You must accept Gathr’s terms of service to complete this purchase.
From $0 / person

The Film

When engineer Dave Feldman reverses his pre-diabetes with a low-carb diet, he feels invincible—until a routine blood test reveals sky-high LDL cholesterol, putting him at odds with decades of medical advice. Torn between feeling the healthiest he’s ever been and warnings of catastrophic heart disease, Dave refuses to accept easy answers. What begins as a personal experiment quickly expands into a global investigation, challenging the mainstream science that shapes our beliefs.

The Cholesterol Code is more than a documentary—it’s a high-stakes David-versus-Goliath battle for truth. What if our fear of cholesterol has been driven by profit over science? What if low-carb and keto diets—dismissed and demonized—hold the key to reversing the global epidemic of chronic disease? Driven by curiosity and grounded in science, the film follows Dave and a team of researchers through a landmark research study using high-resolution heart imaging. The results raise a daring question: have we been fighting the wrong enemy all along?
Title
The Cholesterol Code
Release
2026
Runtime
104 minutes (1 hour 44 minutes)
Rating
Not Rated
Genre
Documentary, Health
Director
Jennifer Isenhart
Origin
United States
Language
English
Ravi Kamepalli Contact Host
Can't find your tickets?
Click Here

Frequently Asked Questions

This is a discussion-based screening, not a promotional session. The goal is to critically examine evolving evidence and different clinical perspectives.
It explores areas where clinical evidence and guidelines may diverge, especially in metabolic health. The intent is critical appraisal, not guideline replacement.
Dave Feldman is an independent researcher who has contributed to discussions on lipid metabolism, particularly in low-carb populations. The session includes clinical interpretation and debate, not endorsement of any single viewpoint.
Dr. Nadir Ali focuses on insulin resistance, metabolic drivers of CVD, and preventive cardiology. The Q&A allows direct engagement on real-world clinical dilemmas.
The discussion will include clinical scenarios, risk assessment approaches, and decision-making frameworks—not just theory.
The screening is followed by a live Q&A session.
Risk stratification beyond LDL Insulin resistance in cardiovascular disease Preventive strategies increasingly seen in clinical practice
No—highly relevant for: Internal medicine Endocrinology/diabetology Family medicine Vascular/wound care
Dietary approaches may be discussed as part of metabolic health strategies, but the session is focused on clinical evidence and risk interpretation, not prescribing a specific diet.
No. The discussion focuses on risk assessment frameworks, not replacing standard therapies. Clinical decisions remain individualized.
To allow peer-level discussion before and after the session, and to share key insights—not for messaging volume.
No—strictly moderated, high-signal clinical discussion only.
Yes. There is an optional voluntary contribution supporting nonprofit clinical education initiatives.
Whether our current cardiovascular risk model—largely lipid-centric—fully captures the role of metabolic health and insulin resistance.
This session is designed as a clinical discussion, not a directive. It will: • Explore evolving evidence • Present different perspectives • Encourage critical thinking It will NOT: • Replace guidelines • Provide one-size-fits-all recommendations Looking forward to a thoughtful exchange.
Powered by GATHR®